28419-74-1

Basic information

• Product Name: 2-(1H-PYRROLO[3,2-B]PYRIDIN-3-YL)ETHANAMINE
• Synonyms: 2-(1H-PYRROLO[3,2-B]PYRIDIN-3-YL)ETHANAMINE;2-{1H-pyrrolo[3,2-b]pyridin-3-yl}ethan-1-aMine;2-(1H-Pyrrolo[3,2-b]pyridin-3-yl)-ethylamine;1H-pyrrolo[3,2-b]pyridine-3-ethanamine
• CAS NO: 28419-74-1
• Molecular Formula: C₉H₁₁N₃
• Molecular Weight: 161.2037
• Mol File: 28419-74-1.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 358.374 °C at 760 mmHg
• Flash Point: 197.852 °C
• Appearance: /
• Density: 1.225 g/cm³
• CAS DataBase Reference: 2-(1H-PYRROLO[3,2-B]PYRIDIN-3-YL)ETHANAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(1H-PYRROLO[3,2-B]PYRIDIN-3-YL)ETHANAMINE(28419-74-1)
• EPA Substance Registry System: 2-(1H-PYRROLO[3,2-B]PYRIDIN-3-YL)ETHANAMINE(28419-74-1)

Safety Data

• Hazardous Substances Data: 28419-74-1(Hazardous Substances Data)

Usage

General Description

2-(1H-Pyrrolo[3,2-b]pyridin-3-yl)ethanamine is a chemical compound with a complex and unique structure. It belongs to the class of organic compounds known as tryptamines, which are characterized by the presence of a core structure composed of a bicyclic indole ring. This particular compound contains a pyrrolopyridine group, and an ethanamine side chain attached to the nitrogen atom. It may be used in medicinal and research applications due to its potential pharmacological properties, such as its ability to interact with neurotransmitter receptors in the brain. However, its specific uses and effects would need to be determined through further study and analysis.

Upstream product

• 23612-34-2 N,N-dimethyl-1-(1H-pyrrolo[3,2-b]pyridin-3-yl)methanamine 
• 554453-19-9 2-(1H-pyrrolo[3,2-b]pyridin-3-yl)acetonitrile 
• 272-49-1 1H-pyrrolo[3,2-b]pyridine 
• 24509-72-6 2-(1H-pyrrolo[3,2-b]pyridin-3-yl)-acetamide 
• 1378810-11-7 2-oxo-2-(1H-pyrrolo[3,2-b]pyridin-3-yl)acetamide 

Downstream Products

• 1312891-85-2 (E)-3-(4-{[2-(1H-pyrrolo[3,2-b]pyridin-3-yl)ethylamino]methyl}phenyl)acrylic acid methyl ester 
• 1312891-47-6 (E)-N-hydroxy-3-(4-{[2-(1H-pyrrolo[3,2-b]pyridin-3-yl)ethylamino]methyl}phenyl)acrylamide 

Relevant articles and documents

Synthesis and SAR of the antistaphylococcal natural product nematophin from Xenorhabdus nematophila

The repeated and improper use of antibiotics had led to an increased number of multiresistant bacteria. Therefore, new lead structures are needed. Here, the synthesis and an expanded structure–activity relationship of the simple and antistaphylococcal amide nematophin from Xenorhabdus nematophila and synthetic derivatives are described. Moreover, the synthesis of intrinsic fluorescent derivatives, incorporating azaindole moieties was achieved for the first time.

Optimization of the in vitro cardiac safety of hydroxamate-based histone deacetylase inhibitors

Histone deacetylase (HDAC) inhibitors have shown promise in treating various forms of cancer. However, many HDAC inhibitors from diverse structural classes have been associated with QT prolongation in humans. Inhibition of the human ether a-go-go related gene (hERG) channel has been associated with QT prolongation and fatal arrhythmias. To determine if the observed cardiac effects of HDAC inhibitors in humans is due to hERG blockade, a highly potent HDAC inhibitor devoid of hERG activity was required. Starting with dacinostat (LAQ824), a highly potent HDAC inhibitor, we explored the SAR to determine the pharmacophores required for HDAC and hERG inhibition. We disclose here the results of these efforts where a high degree of pharmacophore homology between these two targets was discovered. This similarity prevented traditional strategies for mitigating hERG binding/modulation from being successful and novel approaches for reducing hERG inhibition were required. Using a hERG homology model, two compounds, 11r and 25i, were discovered to be highly efficacious with weak affinity for the hERG and other ion channels.

Azaindolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands

The present invention provides a compound of formula I and the use thereof for the therapeutic treatment of disorders relating to or affected by the 5-HT6 receptor.